Kellen Hirsch1,2, Elizabeth Taglauer3, Gregory Seedorf1,4,5, Carly Callahan6, Erica Mandell1, Carl W White4,5, Stella Kourembanas3, Steven H Abman1,4,5. 1. Pediatric Heart Lung Center and. 2. Medical Student Research Track, School of Medicine, and. 3. Division of Neonatology, Boston Children's Hospital-Harvard Medical School, Harvard University, Boston, Massachusetts; and. 4. Pediatric Pulmonology Clinic, Children's Hospital Colorado, Aurora, Colorado. 5. Department of Pediatrics, Anschutz Medical Center, University of Colorado Denver, Aurora, Colorado. 6. University of Southern California, Los Angeles, California.
Abstract
Rationale: Antenatal inflammation with placental dysfunction is strongly associated with high bronchopulmonary dysplasia (BPD) risk in preterm infants. Whether antenatal or postnatal HIF (hypoxia-inducible factor) augmentation can preserve lung structure and function and prevent pulmonary hypertension after intrauterine inflammation is controversial. Objectives: To determine whether antenatal or postnatal prolyl-hydroxylase inhibitor (PHi) therapy increases lung HIF expression, preserves lung growth and function, and prevents pulmonary hypertension in a rat model of chorioamnionitis-induced BPD caused by antenatal inflammation. Methods: Endotoxin (ETX) was administered to pregnant rats by intraamniotic injection at Embryonic Day 20, and pups were delivered by cesarean section at Embryonic Day 22. Selective PHi drugs, dimethyloxalylglycine or GSK360A, were administered into the amniotic space at Embryonic Day 20 or after birth by intraperitoneal injection for 2 weeks. Placentas and lung tissue were collected at birth for morphometric and Western blot measurements of HIF-1a, HIF-2a, VEGF (vascular endothelial growth factor), and eNOS (endothelial nitric oxide synthase) protein contents. At Day 14, lung function was assessed, and tissues were harvested to determine alveolarization by radial alveolar counts, pulmonary vessel density, and right ventricle hypertrophy (RVH).Measurements and Main Results: Antenatal PHi therapy preserves lung alveolar and vascular growth and lung function and prevents RVH after intrauterine ETX exposure. Antenatal administration of PHi markedly upregulates lung HIF-1a, HIF-2a, VEGF, and eNOS expression after ETX exposure.Conclusions: HIF augmentation improves lung structure and function, prevents RVH, and improves placental structure following antenatal ETX exposure. We speculate that antenatal or postnatal PHi therapy may provide novel strategies to prevent BPD due to antenatal inflammation.
Rationale: Antenatal inflammation with placental dysfunction is strongly associated with high bronchopulmonary dysplasia (BPD) risk in preterm infants. Whether antenatal or postnatal HIF (hypoxia-inducible factor) augmentation can preserve lung structure and function and prevent pulmonary hypertension after intrauterine inflammation is controversial. Objectives: To determine whether antenatal or postnatal prolyl-hydroxylase inhibitor (PHi) therapy increases lung HIF expression, preserves lung growth and function, and prevents pulmonary hypertension in a rat model of chorioamnionitis-induced BPD caused by antenatal inflammation. Methods: Endotoxin (ETX) was administered to pregnant rats by intraamniotic injection at Embryonic Day 20, and pups were delivered by cesarean section at Embryonic Day 22. Selective PHi drugs, dimethyloxalylglycine or GSK360A, were administered into the amniotic space at Embryonic Day 20 or after birth by intraperitoneal injection for 2 weeks. Placentas and lung tissue were collected at birth for morphometric and Western blot measurements of HIF-1a, HIF-2a, VEGF (vascular endothelial growth factor), and eNOS (endothelial nitric oxide synthase) protein contents. At Day 14, lung function was assessed, and tissues were harvested to determine alveolarization by radial alveolar counts, pulmonary vessel density, and right ventricle hypertrophy (RVH).Measurements and Main Results: Antenatal PHi therapy preserves lung alveolar and vascular growth and lung function and prevents RVH after intrauterine ETX exposure. Antenatal administration of PHi markedly upregulates lung HIF-1a, HIF-2a, VEGF, and eNOS expression after ETX exposure.Conclusions: HIF augmentation improves lung structure and function, prevents RVH, and improves placental structure following antenatal ETX exposure. We speculate that antenatal or postnatal PHi therapy may provide novel strategies to prevent BPD due to antenatal inflammation.
Authors: Emily J Su; Hong Xin; Ping Yin; Matthew Dyson; John Coon; Kathryn N Farrow; Karen K Mestan; Linda M Ernst Journal: J Clin Endocrinol Metab Date: 2015-01 Impact factor: 5.958
Authors: Roberta L Keller; Rui Feng; Sara B DeMauro; Thomas Ferkol; William Hardie; Elizabeth E Rogers; Timothy P Stevens; Judith A Voynow; Scarlett L Bellamy; Pamela A Shaw; Paul E Moore Journal: J Pediatr Date: 2017-05-17 Impact factor: 4.406
Authors: Bernard Thébaud; Kara N Goss; Matthew Laughon; Jeffrey A Whitsett; Steven H Abman; Robin H Steinhorn; Judy L Aschner; Peter G Davis; Sharon A McGrath-Morrow; Roger F Soll; Alan H Jobe Journal: Nat Rev Dis Primers Date: 2019-11-14 Impact factor: 52.329
Authors: Timothy D Le Cras; Neil E Markham; Rubin M Tuder; Norbert F Voelkel; Steven H Abman Journal: Am J Physiol Lung Cell Mol Physiol Date: 2002-09 Impact factor: 5.464
Authors: Peter M Mourani; Erica W Mandell; Maxene Meier; Adel Younoszai; John T Brinton; Brandie D Wagner; Sanne Arjaans; Brenda B Poindexter; Steven H Abman Journal: Am J Respir Crit Care Med Date: 2019-04-15 Impact factor: 21.405
Authors: Tiziana Cotechini; Maria Komisarenko; Arissa Sperou; Shannyn Macdonald-Goodfellow; Michael A Adams; Charles H Graham Journal: J Exp Med Date: 2014-01-06 Impact factor: 14.307
Authors: Chang Won Choi; Juyoung Lee; Hyun Ju Lee; Hyoung-Sook Park; Yang-Sook Chun; Beyong Il Kim Journal: J Korean Med Sci Date: 2015-08-13 Impact factor: 2.153
Authors: Reiji Ito; Elizabeth A Barnes; Xibing Che; Cristina M Alvira; David N Cornfield Journal: Am J Physiol Lung Cell Mol Physiol Date: 2022-06-28 Impact factor: 6.011
Authors: Alison N Abele; Elizabeth S Taglauer; Maricar Almeda; Noah Wilson; Abigail Abikoye; Gregory J Seedorf; S Alex Mitsialis; Stella Kourembanas; Steven H Abman Journal: Am J Physiol Lung Cell Mol Physiol Date: 2021-12-08 Impact factor: 5.464
Authors: Erick Forno; Steven H Abman; Jagdev Singh; Mary E Robbins; Hiran Selvadurai; Paul T Schumacker; Paul D Robinson Journal: Am J Respir Crit Care Med Date: 2021-08-01 Impact factor: 30.528